Kestra Medical Technologies, a Kirkland-based company selling cardiac monitoring and therapeutic devices, filed for an initial public offering. The company’s revenue more than tripled from $7.6M in fiscal year 2023 to $27.8M in the last fiscal year, which ended in April.
Kestra launched in 2014 and makes wearable devices to detect and respond to sudden cardiac arrest, which is when the heart stops beating normal. The arrest is usually the result of ventricular arrhythmias caused by an electrical malfunction in the heart.
The cardiac event can be deadly if not responded to immediately and kills approximately 475,000 people each year in the U.S.
Kestra’s system, which won FDA approval in 2021, can send an alert to emergency medical service operators after a defibrillation shock. It also features a remote care patient data platform.